Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- BCG’s Efficacy in COVID-19 Not Yet Confirmed: Japan Vaccine Society
April 6, 2020
- Researchers Unlock SAL Inhibitory Mechanism of Obesity Med Orlistat; Potential Treatment for MRSA/Atopic Dermatitis
March 30, 2020
- Otsuka, NCC Develop Comprehensive Genomic Profiling Assay for Blood Cancer
March 27, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir
March 24, 2020
- Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
- COVID-19 Patients in Japan Improved on Plaquenil
March 11, 2020
- Camostat Potential Treatment for COVID-19: German Study
March 11, 2020
- Alvesco Inhibits RNA Replications: NIID
March 9, 2020
- With Sudden Spotlight on Alvesco for COVID-19, Teijin Being Flooded with Inquiries
March 6, 2020
- Asthma Drug Alvesco Possibly Effective for COVID-19
March 4, 2020
- Kyoto Univ., NTT Launch New Company to Analyze, Provide RWD; Label Expansions Eyed for Cancer Drugs
February 5, 2020
- TMDU Research Team Calls for New Hypothesis on Cause of AD; Could Lead to Development of Gene Therapy
January 28, 2020
- Impact of Oligonucleotides - 3: Advances in Modified Oligo Technologies Pave Way for Innovative Drug Arrivals
January 20, 2020
- Nagasaki Univ., Kobe Foundation Tie Up on Clinical Development
January 17, 2020
- Impact of Oligonucleotides - 2: Expert Says Spinraza Changed SMA Treatment Paradigm, Has High Expectation for Zolgensma Too
January 17, 2020
- Impact of Oligonucleotides - 1: Onpattro a Major Advance in FAP Treatment, but Challenges Remain
January 16, 2020
- Leading IBD Care Hospital Switches to Infliximab Biosimilars; Will Others Follow Suit?
January 7, 2020
- 5-Year Cancer Survival Rate Rises 0.3 Point to 66.4%: NCC
December 17, 2019
- 8,000 Die from 2 Drug Resistant Bacteria Annually in Japan: Survey
December 9, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…